



June 13, 2017

## **Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial**

LEXINGTON, Mass., June 13, 2017 /PRNewswire/ -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, announced they will host a conference call and webcast on Wednesday, June 14, 2017 at 8:00 A.M. EDT to discuss results from its Phase 2b Allergic Conjunctivitis Trial.

The dial-in numbers are 1-877-870-4263 for domestic callers and 1-412-317-0790 for international callers. A live webcast of the conference call will also be available on the investor relations page of the Aldeyra Therapeutics corporate website at [www.aldeyra.com](http://www.aldeyra.com).

After the live webcast, the event will remain archived on the Aldeyra Therapeutics website for one year.

### **About Aldeyra Therapeutics**

Aldeyra Therapeutics, Inc. is a biotechnology company devoted to improving lives by inventing, developing and commercializing products that treat diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules. Aldeyra's lead product candidate, ADX-102, is an aldehyde trap in development for ocular inflammation, as well as for Sjögren-Larsson Syndrome and Succinic Semi-Aldehyde Dehydrogenase Deficiency, two inborn errors of aldehyde metabolism. Aldeyra's product candidates have not been approved for sale in the U.S. or elsewhere.

Corporate Contact:  
Stephen Tulipano  
Aldeyra Therapeutics, Inc.  
Tel: +1 781-761-4904 ext. 205  
[stulipano@aldeyra.com](mailto:stulipano@aldeyra.com)

Investor Contact:  
Chris Brinzey  
Westwicke Partners  
Tel: 339-970-2843  
[Chris.brinzey@westwicke.com](mailto:Chris.brinzey@westwicke.com)

Media Contact:  
Cammy Duong  
MacDougall Biomedical Communications  
781-591-3443  
[cduong@macbiocom.com](mailto:cduong@macbiocom.com)

To view the original version on PR Newswire, visit:<http://www.prnewswire.com/news-releases/aldeyra-therapeutics-schedules-conference-call-and-webcast-to-announce-results-from-allergic-conjunctivitis-phase-2b-clinical-trial-300473316.html>

SOURCE Aldeyra Therapeutics, Inc.

News Provided by Acquire Media